Coronavirus (COVID-19): Latest information

We have made the difficult decision to close The Royal Marsden Cancer Charity offices in both the Chelsea and Sutton hospitals due to COVID-19. Our charity team will be working remotely and can be contacted via email - [email protected]. Post sent to the office will be checked once a week.


Investing in radiotherapy

Radiotherapy helps cure 40 percent of cancer patients.

Radiotherapy helps cure 40 per cent of cancer patients. So it’s exciting news that The Royal Marsden in Chelsea now has a third Varian TrueBeam radiotherapy machine. The Charity has funded the upgrade to the infrastructure needed to install the machine while the machine itself was paid for by NHS England as part of their plan to update radiotherapy equipment across the country. 


The TrueBeam delivers all forms of advanced external-beam radiotherapy: image-guided radiotherapy (IGRT); intensity-modulated radiotherapy (IMRT); stereotactic body radiotherapy (SBRT); and volumetric modulated arc therapy (VMAT) across a range of cancer types including breast, lung, head and neck, prostate, gastrointestinal and gynaecological cancers.


This state-of-the-art Truebeam joins The Royal Marsden’s suite of the very latest radiotherapy technology that supporters of the Charity helped fund. This includes the CyberKnife, the UK’s first MR Linac machine and recently updated linear accelerator heads.